Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $104.3 million.

  • Rhythm Pharmaceuticals' Total Current Liabilities rose 682.55% to $104.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.3 million, marking a year-over-year increase of 682.55%. This contributed to the annual value of $115.5 million for FY2024, which is 10925.86% up from last year.
  • Rhythm Pharmaceuticals' Total Current Liabilities amounted to $104.3 million in Q3 2025, which was up 682.55% from $129.5 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Total Current Liabilities' 5-year high stood at $129.5 million during Q2 2025, with a 5-year trough of $16.8 million in Q1 2021.
  • For the 5-year period, Rhythm Pharmaceuticals' Total Current Liabilities averaged around $59.5 million, with its median value being $47.3 million (2022).
  • Within the past 5 years, the most significant YoY rise in Rhythm Pharmaceuticals' Total Current Liabilities was 18055.79% (2022), while the steepest drop was 833.12% (2022).
  • Over the past 5 years, Rhythm Pharmaceuticals' Total Current Liabilities (Quarter) stood at $43.4 million in 2021, then fell by 8.33% to $39.8 million in 2022, then skyrocketed by 38.67% to $55.2 million in 2023, then surged by 109.26% to $115.5 million in 2024, then fell by 9.74% to $104.3 million in 2025.
  • Its last three reported values are $104.3 million in Q3 2025, $129.5 million for Q2 2025, and $111.8 million during Q1 2025.